Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Clinical Trials Arena on MSN

MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Zacks.com on MSN

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
Business Wire

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Isl…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript

Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...